five

Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non–vitamin K antagonist oral anticoagulants

收藏
Taylor & Francis Group2020-05-22 更新2026-04-16 收录
下载链接:
https://tandf.figshare.com/articles/Healthcare_costs_of_stroke_and_major_bleeding_in_patients_with_atrial_fibrillation_treated_with_non_vitamin_K_antagonist_oral_anticoagulants/7944338/1
下载链接
链接失效反馈
官方服务:
资源简介:
<b><i>Objective:</i></b> To assess long-term healthcare costs related to ischemic stroke and systemic embolism (stroke/SE) and major bleeding (MB) events in patients with non-valvular atrial fibrillation (NVAF) treated with non-vitamin K antagonist oral anticoagulants (NOACs). <b><i>Material and Methods:</i></b> Optum’s Clinformatics Data Mart database from 1/2009–12/2016 was analyzed. Adult patients with ≥1 stroke/SE hospitalization (index date) were matched 1:1 to patients without stroke/SE (random index date), based on propensity scores. Patients with an MB event were matched to patients without MB. All patients had an NOAC dispensing overlapping index date, ≥12 months of eligibility pre-index date, and ≥1 NVAF diagnosis. The observation period spanned from the index date until the earliest date of death, switch to warfarin, end of insurance coverage, or end of data availability. Mean costs were evaluated: (1) per-patient-per-year (PPPY) and (2) at 1, 2, 3, and 4 years using Lin's method. <b><i>Results:</i></b> The cost differences were respectively $48,807 and $28,298 PPPY for NOAC users with stroke/SE (N = 1,340) and those with MB (N = 3,774) event compared to controls. Cost differences of patients with versus without stroke/SE were $49,876, $51,627, $57,822, and $60,691 at 1, 2, 3, and 4 years post-index, respectively (P <b><i>Limitations:</i></b> Limitations include unobserved confounders, coding and/or billing inaccuracies, limited sample sizes over longer follow-up, and the underreporting of mortality for deaths occurring after 2011. <b><i>Conclusions:</i></b> The incremental healthcare costs incurred by patients with versus without stroke/SE was nearly twice as high as those of patients with versus without MB. Moreover, each additional year up to 4 years after the first event was associated with an incremental cost for patients with a stroke/SE or MB event compared to those without an event.
提供机构:
Francois Laliberte
创建时间:
2019-04-03
二维码
社区交流群
二维码
科研交流群
商业服务